危機管理 Crisis Management – ページ 23 – ワールドソルーションズLLC

Science and Technology 科学技術 Vol.14 ／ #Coronavirus #コロナウイルス Vol.15（pharmaceutical products 医薬品 Vol.6：drugs 治療薬）

All the below links and excerpts are in English.

Tocilizumab/Atlizumab（Actemra®）に係るリンクと当方作成の抜粋を取り急ぎ以下のとおり貼っておきます。

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial (w PDF; 10/20/2020) | @JAMANetwork
PDF　

Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis (w PDF; 11/05/2020) | @CMIJournal
Conclusion
Cumulative moderate certainty evidence shows that tocilizumab reduces the risk of mechanical ventilation in hospitalized COVID-19 patients. While RCTs showed that tocilizumab did not reduce short-term mortality, low certainty evidence from cohort studies suggests an association between tocilizumab and lower mortality. We did not observe a higher risk of infections or adverse events with tocilizumab use. This review will continuously evaluate the role of tocilizumab in COVID-19 treatment.

Efficacy of Tocilizumab on Patients With COVID-19 (08/24/2020) | @MGHMedicine,@genentech ClinicalTrials.gov @nlm_news
Brief Summary:
This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation.
The aim of this study is to test the effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.
Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures. Multi-organ dysfunction will be measured as the incidence of the following composite endpoint (mechanical ventilation, renal replacement therapy, mechanical support, need for inotropes or vasopressors, liver dysfunction (increased bilirubin), and all-cause mortality). We will also assess multiple pre-specified secondary (exploratory) endpoints and safety endpoints.
We hypothesize that, as compared to placebo, tocilizumab will reduce transfer to the ICU, need for mechanical ventilation, increase rates of hospital discharge in patients diagnosed with severe COVID-19 infection and evidence of exaggerated inflammatory response.

New results from a once-promising therapy show the difficulty of treating covid-19: In one study, the drug, tocilizumab, reduced risk of death in ICU patients, but two others found negligible results with slightly different patients (10/21/2020) | @washingtonpost
Studies offer little hope for tocilizumab in treating COVID (10/20/2020) | @CIDRAP
Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia (10/20/2020) | @JAMANetwork
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 (10/20/2020) | @JAMANetwork

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 (10/21/2020) | @NEJM
Tocilizumab for COVID-19? Three Studies Yield Mixed Findings (10/20/2020) | @JWatch
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (w PDF; 21/10/2020) | Journal of Translational Medicine
Appropriate use of tocilizumab in COVID-19 infection (w PDF; 10/2020) | International Journal of Infectious Diseases @ElsevierConnect
PDF　

Roche’s Actemra helps keep coronavirus patients off ventilators despite earlier trial flop (09/18/2020) | @FiercePharma
…Roche is also pairing Actemra with Gilead Sciences’ antiviral Veklury, better known as remdesivir, in the phase 3 Remdacta trial. Eli Lilly’s JAK arthritis med Olumiant combined with Veklury helped patients recover faster in a recent trial run by the National Institute of Allergy and Infectious Diseases.

Tocilizumab/IL-6 Inhibitors | @RealTimeCOVID19
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. | @WHO
Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies (w PDF; 23/09/2020) | @OUPAcademic
Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease (09/16/2020) | @NCBI
Efficacy of tocilizumab in COVID‐19: A systematic review and meta‐analysis (w PDF; 12/09/2020) | @WileyGlobal
Glucocorticoids, tocilizumab may reduce complications in COVID-19-related cytokine storm (09/03/2020) | @HealioRheum
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study (w PDF; 08/14/2020) | @TheLancetRheum
Tocilizumab in patients with severe COVID-19: a retrospective cohort study (w PDF; 08/01/2020) | @TheLancetRheum
Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan (04/08/2020) | @chugai_cc
What is the role of the IL-6 inhibitor tocilizumab (Actemra) in the treatment of coronavirus disease 2019 (COVID-19)? (11/10/2020) | @Medscape

Science and Technology 科学技術 Vol.13 ／ #Coronavirus #コロナウイルス Vol.14（pharmaceutical products 医薬品 Vol.5：drugs 治療薬）

All the below links and excerpts are in English.

Convalescent plasma（回復期血漿療法）に係るリンクと当方作成の抜粋を取り急ぎ以下のとおり貼っておきます。

The FDA has authorized convalescent plasma treatment for coronavirus patients – but some scientists worry it’s too soon (08/26/2020) | @businessinsider
During the 1918 Spanish flu pandemic, doctors discovered they could treat sick patients with the blood of those who had already recovered. …
Antibodies develop in plasma, the liquid portion of blood – they’re part of our body’s natural response to a foreign pathogen. So the idea behind the treatment is to help sick people mount an antibody response to the virus by transferring plasma intravenously from those who already have antibodies.
“What we really need are drugs that, when given early, can prevent a symptomatic person from requiring hospitalization or very dramatically diminish the time that they’re symptomatic,” …
… Plasma must be transferred quickly from a donor to a recipient – and both must have compatible blood types. The quantity is also limited, since it depends on blood donations. …
A national study of 35,000 hospitalized coronavirus patients, which is still awaiting peer review, found that patients less than 80 years old who weren’t on a respirator and received plasma containing high levels of antibodies within three days of their diagnosis had a 35% lower mortality rate than those who were treated four or more days after their diagnosis.
The process of creating hyperimmune globulin involves pooling plasma from recovered patients and heat-treating it so that any remaining pathogens get destroyed. The result is a vial of medicine with consistent antibody levels that can easily be administered to patients. The drug focuses on the most common antibody found in blood ? immunoglobulin G (IgG) – which usually confers long-term immunity.
… The Mount Sinai Hospital … working with Emergent BioSolutions, a Maryland-based biopharmaceutical company, to develop a hyperimmune globulin product. …
… “The Fight Is In Us” … The coalition hopes to secure regulatory approval from the FDA by the end of 2020. …

Why we don’t know if convalescent plasma works to treat Covid-19 (08/29/2020) | @qz
… “There’s no money to be made in plasma,” says Jeffrey Henderson, a physician and infectious disease researcher at Washington University St. Louis. Because it’s a biological product, it can’t be patented or sold for a profit. As a result, no single research group or company has funded a large, randomized controlled trial of plasma, the highest standard of clinical evidence. …
It isn’t cheap: Between 2012 and 2018, the median cost of bringing a drug to market was $985 million, about $19 million of which goes to clinical research. Typically, drug companies are happy to invest. Once their product is approved, they can sell it at a price that makes up for the loss (and then some). …
…expanded access program (EAP), a network spearheaded by researchers at the Mayo Clinic in Rochester, Minnesota…
… Eventually, the EAP program got some funding from the US Biomedical Advanced Research and Development Authority…
…Albert Einstein College of Medicine in New York…

Takeda, CSL-led alliance starts scaling up production of COVID-19 plasma therapy as phase 3 kicks off: report (10/13/2020) | @fiercepharma
… The clinical batches were produced at Takeda’s U.S. facility in Georgia and CSL’s site in Bern, Switzerland. The National Institute of Allergy and Infectious Diseases in the U.S. is running the trial. …
Eli Lilly and Regeneron have reported encouraging results for their antibody cocktails, each of which combines two synthetic monoclonal antibodies. While those products have less antibody variety, they only used donated plasma to help identify the antibodies with the most promise in fighting COVID. …

DOD Awards $750,000 to Plasma Technologies, LLC for Manufacturing of Convalescent Plasma Products Using a Novel Process in Support of the U.S. COVID-19 Response (08/17/2020) | DOD
… The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) partnered with HHS and the Army Contracting Command – Aberdeen Proving Ground (ACC-APG), to select Plasma Technologies, LLC for this cooperative agreement. Plasma Technologies, LLC, a plasma biologics technology company, is located in Charleston, South Carolina. …

Plasma Therapy Global Market Report 2020-30: Covid 19 Growth and Change (07/30/2020) | CISION
Major players in the plasma therapy market are Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Arthrex, Inc., Biotest AG, China Biologic Products Holdings, Inc., DePuy Synthes Companies, CSL Limited, Grifols, S.A., Octapharma, and Terumo BCT, Inc. …
The global plasma therapy market is expected to grow from $187.67 million in 2019 to $246.95 million in 2020 at a compound annual growth rate (CAGR) of 31.6%. The growth is mainly attributed to the COVID-19 outbreak and the urgent need to treat a growing number of cases. …
… In March 2020, Takeda Pharmaceutical Company Limited has initiated a plasma-therapy, Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), which is termed as TAK-888 for treating COVID-19. The TAK-888 utilizes the plasma collected from convalescent donors who have been cured of COVID-19 and is administered to the patient suffering from COVID-19.

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration (05/07/2020) | @TakedaPharma
… In addition to those announced at its inception – Biotest, BPL, CSL Behring, LFB, Octapharma and Takeda – the Alliance welcomes new industry members ADMA Biologics, BioPharma Plasma, GC Pharma, and Sanquin. …
In parallel, the Alliance has confirmed it will work with the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH to test the safety, tolerability and efficacy of the hyperimmune therapy in adult patients with COVID-19. This global study is currently anticipated to start in the summer…
“Hyperimmune globulin therapy has the potential to be one of the earliest treatment options for COVID-19, and we look forward to working with NIAID and health authorities to bring this therapy to patients as early as possible,” …
… To amplify awareness, the Alliance has gained support from large organizations outside of the plasma industry. Examples of those offering resources to the Alliance include Microsoft and Uber Health. Microsoft is providing technology support, including the Alliance website and the Plasmabot for donor recruitment. The Plasmabot streamlines the process for a potential donor to quickly gain information about their nearest collection center from across the member network. In parallel, Uber Health has agreed to donate 25,000 round-trip rides to transport potentially eligible donors to and from plasma collection centers. …

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy (04/06/2020) | @TakedaPharma
Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine…

Trump admin funds plasma company based in owner’s condo (02/11/2020) | @ABCNews
Plasma Technologies LLC, Pepcid, ApiJect Systems America, Novavax
ThermoGenesis and ImmuneCyte Joint Venture Developing Several Convalescent Plasma and Antibody Therapeutic Approaches Against COVID-19, Featured on FOX40 and Other Local News Outlets (04/24/2020) | @biospace
Takeda, Other Firms Test Covid-19 Convalescent-Plasma Treatment: NIH funds study of high antibody concentrations combined with the antiviral remdesivir (10/08/2020) | @WSJ

U.S.A. アメリカ Vol.128（Illinois イリノイ州 Vol.3: healthcare corporations ヘルスケア会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

Illinois Vol.14 (corporations: Baxter International)

上記リンク内に無い本日までのツイート

Learn more about a new study published in @CritCareMed showing blood purification with our Oxiris filter set can play a role in the management of severely ill #COVID19 patients: https://t.co/DhG96Sngmv pic.twitter.com/3lmhX7889A

— Baxter International (@baxter_intl) October 27, 2020

　https://twitter.com/baxter_intl/status/1253397642891198464

Baxter launches new indication for its oXiris blood purification set at #ESCIM: https://t.co/O7tq5Vmd7T

— Baxter International (@baxter_intl) September 26, 2017

　https://twitter.com/baxter_intl/status/1260972247440900097

As a leader in the ICU, our team in Canada transformed continuous renal replacement therapy (CRRT) “refresher” trainings into inspiring sessions that empowered 500+ nurses. Learn more on how we’re partnering with healthcare providers in critical care: https://t.co/DqHiUOdCYL pic.twitter.com/LaLTc3bFqi

— Baxter International (@baxter_intl) February 27, 2019

Learn more about the U.S. FDA Emergency Use Authorization we received for our Regiocit replacement solution for adults requiring continuous renal replacement therapy and regional citrate anticoagulation during the #COVID19 pandemic. https://t.co/zgSHLz9bk7 pic.twitter.com/C33ZYjmJ5X

— Baxter International (@baxter_intl) August 14, 2020

More from @ASN #KidneyWk: PrisMax Is our next-generation platform for continuous renal replacement therapy (CRRT) and therapeutic plasma exchange (TPE) that just launched in the US. Visit Baxter booth 1527 for demos. https://t.co/1k55e4TWku #CRRT #kidneycare pic.twitter.com/GduADcFtvY

— Baxter International (@baxter_intl) November 8, 2019

　https://twitter.com/baxter_intl/status/1254872455186993153

We’re excited to share the news of the launch of the PrisMax system in the U.S. Our next-generation platform offers innovative technology and flexibility to meet the unique demands of the ICU. https://t.co/x5se4pjCFu pic.twitter.com/puNcopcXng

— Baxter International (@baxter_intl) July 30, 2019

Just two weeks ago, we announced CE Mark of our next-gen system for CRRT & organ support therapies. Today, we’re proud to share that hospitals in Europe are already adopting PrisMax – with the first confirmed patients in Sweden & France. Learn more, here: https://t.co/YsgymkSp82 pic.twitter.com/cmp4TA6QU5

— Baxter International (@baxter_intl) November 14, 2018

Want to learn about a tool that can support patient blood management strategies? Read our whitepaper to see how a surgical team used the VIBe SCALE to implement a common language to discuss bleeding severity and complications in their practice: https://t.co/bKDrnB1u2q pic.twitter.com/uWLemWRQwF

— Baxter International (@baxter_intl) November 10, 2020

A central part of any patient blood management strategy is to choose the right products for the right bleed. Learn more about the VIBe SCALE, a surgeon-validated scale that clinicians can use to objectively and reliably assess bleeding severity: https://t.co/RN8XNnU5fs pic.twitter.com/TfBAfTCTR7

— Baxter International (@baxter_intl) November 10, 2020

“With current shortages of blood and blood products due to #COVID19, patient blood management (PBM) is more important than ever. We’re committed to raising awareness around the need for effective PBM strategies.” – Wil Boren, President, Advanced Surgery https://t.co/NJdimB30cT pic.twitter.com/GPAOLpqhrR

— Baxter International (@baxter_intl) November 9, 2020

"These findings could have real implications for treating patients moving forward." Hear from Prof. Lui Forni, BSc, Ph.D., https://t.co/Ve0AlOX8Pq, MRCPI, AFICM on the FRESH Clinical Trial, which is featured in @accpCHEST’s October #journalCHEST: https://t.co/IiP01VLvwQ pic.twitter.com/eMMK7SfYqx

— Baxter International (@baxter_intl) October 21, 2020

　https://twitter.com/baxter_intl/status/1235582637282123778

#MedTech innovator @baxter_intl is providing #KidneyCare technologies to #Covid19 patients suffering from acute kidney injury through an emergency use authorization. Learn more about our valued customer's #ContinuousRenalReplacementTherapy (CRRT) Sets: https://t.co/sBGU16JSDQ.

— Partstat (@Partstat) September 2, 2020

A hollow ﬁber membrane bioreactor uses temperature shifts to harvest 3D mini-tissues without extensive surface treatment @baxter_intl @RWTH

Read the #openaccess article: https://t.co/6QeT8kgw3e pic.twitter.com/vbhdcJack0

— Advanced Sci News (@AdvSciNews) October 24, 2020

Pre-COVID-19 coronavirus antibodies fail to neutralize SARS-CoV-2 https://t.co/pfraucgjQC @baxter_intl @biorxivpreprint #Immunoglobulin #Pandemic #Virus #Antibodies #Coronavirus #COVID19 #SARSCoV2

— News Medical (@NewsMedical) August 2, 2020

What a kind, generous gift in memory of a man who gave so much to our community and our students! @MHEdF @Dr_JakeLong @baxter_intl https://t.co/tsEmCXOH1Q

— Mountain Home Public Schools (@BombersMh) September 16, 2020

I wrote a blog entry at KidneyViews. This entry is about the proposed expansion of TPNIES to home dialysis equipment. My goal is to help you craft a comment letter to @CMSGov.@ASNKidney @baxter_intl @hdunews @KidneyPatients @nkf @NxStage @OutsetMedical https://t.co/2qNIA1hf5w

— Eric Weinhandl (@eric_weinhandl) August 24, 2020

RT @MedTechDaily Next COVID-19 device shortage? ‘Smart’ infusion pumps https://t.co/ADCn4tGnet #coronavirus #medtech #meddevice @ismp1 @IvenixInc @baxter_intl @ICU_Medical pic.twitter.com/i5uwWkOd6Q

— MassDevice (@MassDevice) April 27, 2020

Congrats to engineering technology professor Driss Bennhaddou for being named a finalist for a funded research opportunity with @baxter_intl after a worldwide search on @HALOdotscience. Learn about his research and how it could help dialysis patients. https://t.co/ZAJO9cuOgE pic.twitter.com/8GtdRix01Z

— UH College of Technology (@UHCOT) June 15, 2020

.@chfund recieved a $100K grant from @baxter_intl to expand telehealth services for children in #NorthCarolina’s #rural McDowell & Avery Counties. #ruralhealth https://t.co/oXZv7ReNHk

— Center for Optimizing Rural Health (@RuralHealthTAMU) March 18, 2020

Explore this new #technology! @Medtronic, @baxter_intl, @TeleflexInc, @DePuySynthes, @CookMedical, @ConvaTec, @MeritMedical, @JNJMedDevices, @BDandCo, @bostonsci, @pfizer, @Medline

— UF Innovate (@UFInnovate) November 2, 2020

@uarkbme student, Alexandria Patton, shared a couple of photos with us from her summer internship at @baxter_intl where she worked as a product development engineer! Good luck this semester and thank you for sharing!#uark pic.twitter.com/q8O2b67PWl

— U of A Engineering (@UofA_Engr) August 29, 2020

https://twitter.com/Paul_Wischmeyer/status/1258147535354425344

"Gujarat the destination of choice for foreign investors and we look forward to partnering with you," said Shri. M.K.Das, IAS. Prin Secy to CMO, Industries, Mines at the @USIBC conference @IndiaChamber @BankofAmerica @baxter_intl @Equifax @Xyleminc @IBM #iccmission #Gujarat #STEM pic.twitter.com/ibmtnkYwRw

— India Chamber USA (@indiachamber) July 31, 2020

#AdvantageIndia

A robust manufacturing ecosystem & favourable schemes make Maharashtra an ideal destination for #auto, #pharma & #engineering companies such as @bajaj_ltd, Wockhardt, @CP_News, @Siemens and @baxter_intl!
Learn more: https://t.co/JwYId7zZgl
#InvestIndia pic.twitter.com/xumOmZrDqA

— Invest India (@investindia) June 18, 2020

#InvestIndiaForIndia
Mr. Navin Sharma, Director, Government Affairs & Public Policy at @baxter_intl, congratulates @investindia team for their remarkable work ensuring business continuity during the #COVID19outbreak in India! Visit: https://t.co/VlbfWYav8n @PMOIndia @DIPPGOI pic.twitter.com/xDJl5TH0e1

— Invest India (@investindia) March 31, 2020

#WorldSmileDay is coming up, so we’re celebrating our partner @baxter_intl. We’re working together to make a positive impact on the lives of people affected by cleft in #India. Find out how https://t.co/wRKXhmmETj pic.twitter.com/zdKlDmZrqp

— Operation Smile (@operationsmile) September 28, 2020

Leader in Continuous Renal Replacement Therapy, American company @baxter_intl offers a unique technology for patients with acute kidney injury, one of the causes of death of COVID-19. Baxter is also committed to working w/ health workers to advance therapy options. pic.twitter.com/V7P4Jf7DJJ

— U.S. Embassy Bangkok (@USEmbassyBKK) April 23, 2020

In #Europe’s World, @baxter_intl’s Cristiano Franzi argues for the benefits of the transition from hospital to home-care for #ChronicPatients. This feeds into the debate on the #EU’s upcoming health preparedness and resilience plans. Read below! https://t.co/oFReh14SEF

— Friends of Europe (@FriendsofEurope) November 9, 2020

"We've transitioned to a 24/7 production schedule for the next four to six weeks to supply about 130 per cent capacity." Great story that includes how @baxter_intl is stepping up to produce as many IV bags as possible for Canadian patients. https://t.co/B9nNml73bF

— Medtech Canada (@Medtech_Canada) March 27, 2020

Congratulations to @BioTalentCanada @abbvie @baxter_intl and @biogen for being recognized as one of the Best Workplaces in Healthcare!

Full list: https://t.co/I7QECN2t8O @Research_MB pic.twitter.com/q2dgQAqZBn

— Bioscience Association Manitoba (@BioscienceMB) September 15, 2020

HDU's work is made possible with the generosity of our sponsors. We'd like to take a moment to recognize and thank our sponsors for their support. @NxStage @OutsetMedical @DialityI @InnaVasc @baxter_intl Redsense Medical @satellitehealth and T.N.T. Moborg #ASNKidney #kidneywk pic.twitter.com/3yM2fn1nmC

— Home Dialyzors News (@hdunews) October 22, 2020

https://twitter.com/STBHF/status/1300522576242855936

Generous funding from @baxter_intl will allow the CHF-supported Center for Rural Health Innovation’s Health-e-Schools Telemedicine Program to expand #telehealth services to nearly 10,000 pre-K through 12th grade students and school staff in North Carolina. https://t.co/xblrsInYqD

— chfund (@chfund) March 2, 2020

Listen to "https://t.co/V8DwmyugxU 58 – How to be a Great CEO in a Crisis" by Murray Newlands ⚓ https://t.co/khSRsp4Bal @HarryKraemerJr of @KelloggSchool, former Chairman & CEO @Baxter_Intl, and author of @ValuestoAction &@BecomingBest #ceo #Crisis #Leadership

— Murray Newlands (@MurrayNewlands) April 7, 2020

We are immensely excited to partner with @baxter_intl on the launch of CKD&Me, a unique app that tailors its educational content to #CKD patients’ individual learning needs. #patientengagement #digitalhealth #empowerement https://t.co/RUdyyVxqfJ

— ayogo (@ayogo) November 6, 2019

Consul General David Gainer recently toured @baxter_intl’s compounding facility in Canning Vale.

It prepares lifesaving medicines including chemotherapy, antibiotics, nutrition and analgesics which are sent across WA (200,00+ units a year!). #USwithAUS pic.twitter.com/9lJB2gYYt8

— US Consulate Perth (@uscongenperth) August 5, 2020

Great meeting last week with Joe Almeida the CEO of @baxter_intl to discuss @HHSGov's #KidneyHealth Initiative and @Kidney_X. pic.twitter.com/wwGlTe0n3i

— Eric D. Hargan (@DepSecHargan) January 27, 2020

.@BiocomSFExecDir shares how the emerging biomedical industry is shaping the East Bay’s life sciences workforce. Thx to @cityofhayward for bringing industry leaders @LonzaGroup @reflexionmed @baxter_intl @illumina and govt officials together to partner and advance growth. pic.twitter.com/LFTr94sHti

— Biocom in SF (@BiocominSF) December 3, 2019

Thank you, @Baxter_intl, for your $100,000 donation to #RedCross. We appreciate your commitment to helping people affected by disasters, big and small! #CBSChicagoCares #GivingTuesday @ChicagoRedCross @IrikaSargent @tvbrad pic.twitter.com/tfVnshGGVY

— CBS Chicago (@cbschicago) December 3, 2019

The #mHUBFIRESeries panel discussion is here! Join us at 5PM to learn about how far #additive #mfg has come and where it's going. Register now to hear from leaders at @baxter_intl, @EOSGmbH, @NIUlive, @shure, @Stratasys, @ULdialogue, and @3DegreesCompany: https://t.co/z7wQ2X7CpJ pic.twitter.com/dNuQaMQEfR

— mHUB (@mHUBChicago) November 12, 2019

ANZICS would like to thank our Sponsors for the CTG Winter Research Forum Webinar. Our Sponsors are integral to the success of all our events we thank @Baxter_intl @Spiralweb @CSL for continued support. For more info visit: https://t.co/JiDO5Ep60X pic.twitter.com/Iw1RD6HhWa

— ANZICS Clinical Trials Group (@anzicsctg) August 13, 2020

Congratulations to our members who made the 100 Best Corporate Citizens list for 2020! @Merck @baxter_intl @abbvie @AbbottNews @BDandCo @pfizer @bmsnews https://t.co/Lgwvgj0gWI

— @pqmd (@pqmd) June 18, 2020

#WorldKidneyDay is tomorrow! We are grateful for the support of @AstellasEurope @AstraZeneca @baxter_intl @Danone @Fresenius and @JanssenGlobal
#KidneyDisease #KidneyHealthforEveryoneEverywhere pic.twitter.com/oAs85ngeWI

— World Kidney Day (@worldkidneyday) March 11, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Global Vomiting Treatment Market Booming Worldwide with Sanofi, Pfizer Inc, Solvay, Teva Pharmaceutical Industries Ltd, Eisai Co., Ltd, Kyowa Kirin Co., Ltd, Baxter, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals… https://t.co/RnewuE6RR5 pic.twitter.com/DUudxj2zHb

— Science Examiner (@ScienceExaminer) October 7, 2019

North America Anesthesia Drugs Market 2019-2024: Baxter International, Fresenius, Eisai, Roche, and B. Braun Melsungen Hold Substantial Market Shares – https://t.co/guyiBzPH8C https://t.co/jOB6n9Ja7t pic.twitter.com/3dojAen4Nx

— Latest News from Business Wire (@NewsFromBW) June 21, 2019

European Hemostats & Sealants Market by Brand (Hemopatch [Baxter], Tachosil [Takeda], Veriset [Medtronic], Avitene [C.R Bard], Sangustop [B Braun], Lyostypt [B Braun]) – Forecast to 2024https://t.co/vE7GS3IiD9 #news #pharma #pharmiweb

— Pharma News (@pharminews) March 24, 2020

Research on Fertility Drug Market (Post COVID-19 impact) with Top Players:Berlex Laboratories, Baxter, Ferring Pharmaceuticals, Janssen, Pfizer, Takeda, P&G, Roche, Eli Lilly, Merck, and Bayer https://t.co/AjNX9r9nND

— @ReportsandMarkets (@ReportsMarkets) November 9, 2020

Global Plasma Protein Therapeutics Market Growth, Trends, and Forecasts 2020-2025: Key Players are Takeda Pharma, Octapharma, Grifols, CSL Behring, Biotest, Baxter, and China Biologic Products – https://t.co/8vPVgQlQhj https://t.co/8TVsJGSNee

— Pharmacutical Daily (@PharmacDaily) October 27, 2020

Healthcare Nutrition Market Trends, Growth, Industry Share, Size, Top Leaders-Medtrition, Baxter, B. Braun Melsungen AG, Mead Johnson & Company, LLC., Otsuka Pharmaceutical Co., Ltd and COVID-19 Impact Analysis 2027https://t.co/GUrhN8O2eQ #news #pharma #pharmiweb

— Pharma News (@pharminews) September 15, 2020

Healthcare Nutrition Market Trends, Growth, Industry Share, Size, Top Leaders-Medtrition, Baxter, B. Braun Melsungen AG, Mead Johnson & Company, LLC., Otsuka Pharmaceutical Co., Ltd and COVID-19 Impact Analysis 2027 – The Daily Chronicle https://t.co/EQbHSUII4d

— MyMartialArtsTV (@MyMartialArtsTV) September 19, 2020

United States Parenteral Nutrition Products Market Progresses for Huge Profits by 2022 With Top Market Players Baxter International, Hospira, B. Braun Melsungen, Grifols International, Fresenius Kabi, Otsuka Pharmaceutical Factory, Actavis https://t.co/vWnyCwS7fW via @openPR

— Michael Jaikishan (@Michaeljaikish1) November 22, 2018

I guess we dont learn the first time: Daiichi buying Ranbaxy, Mylan buying Strides (injectables) and now Baxter buying Claris. There are no short-cuts to compliance and making a quality product https://t.co/ZBuD6Olq6v

— Dinesh S. Thakur (@d_s_thakur) July 22, 2018

Thank you to our sponsors at #FISHIS20 #Online – @Pfizer_UK, @MSDintheUK, @GamaHealthcare, @baxter_intl, Shionogi and Eumedica

Make sure you visit them in our sponsor forum@HIS_infection #IPC #HISevents #InfectionPrevention pic.twitter.com/a3iSIEtqjJ

— FIS / HIS International 2020, 9 – 11 November 2020 (@HISConf) November 10, 2020

That's a wrap on day one of the #SepsisAllianceSummit! Thank you to our conference sponsors for your support: @baxter_intl @Immunexpress @Wello_Inc @thermofisher @Inflammatix_Inc @BeckmanDx @CytoSorbents Erin Kay Flatley Memorial Foundation @Roche @T2Bio @AdaptiveBiotech pic.twitter.com/wZPczkhg40

— Sepsis Alliance (@SepsisAlliance) September 16, 2020

Australia オーストラリア Vol.10（pharmaceutical corporations 製薬会社）

All the below links and tweets are in English.

取り急ぎ以下貼っておきます。

CSL（豪）の子会社
Pennsylvania Vol.11 (corporations: CSL Behring) / Australia Vol.29
UK Vol.173 (pharmaceutical corporations: Seqirus) / Australia Vol.30

上記リンク内に無い本日までのツイート

CSL #FlashbackFriday – 10 Decades in 10 Weeks
1946 to 1956: CSL is manufacturing polio vaccine, a wide range of human and veterinary vaccines, antisera to some of Australia's most venomous snakes and spiders, insulin, penicillin and a suite of blood products. pic.twitter.com/XXkR5KPiD7

— CSL (@CSL) November 5, 2020

https://twitter.com/SamDForever1/status/1325970911258836992

Coronavirus vaccine production begins in Australia before Oxford-AstraZeneca's products last stage of approval @AstraZeneca @csl #Vaccine #Covid19 #Coronavirus https://t.co/U8zKQWp6QX pic.twitter.com/6J6sHNaypJ

— ProTech Recruitment Ltd (@ProTechLtd) November 9, 2020

.@CSL began manufacturing the University of Oxford/AstraZeneca AZD1222 Covid-19 vaccine candidate at its facility in Broadmeadows in northern Melbourne today.https://t.co/xBb64K7DHA #COVID19 #vaccine #manufacturing

— AustralianManufacturingForum (@AuManufacturing) November 9, 2020

Global #biotech company @CSL has commenced the manufacture of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne – a further endorsement for the city’s thriving biotech and #advancedmanufacturing capabilities https://t.co/vb5JAlVy0F pic.twitter.com/dtHis3oOWm

— Invest Victoria (@InvestVictoria) November 9, 2020

.@CSL commences manufacture of @UniofOxford /@AstraZeneca vaccine candidate: https://t.co/6CjpTf2qNL

— AUS Manufacturing (@AustralianM) November 9, 2020

https://twitter.com/DayofImmunology/status/1325371202831962112

A great example of how videos can assist in communicating share plans to employees by Australian company @CSL #EmployeeOwnership #EmployeeOwned https://t.co/drAi6zwle7

— Employee Ownership Australia (@EOwnership) November 6, 2020

This is quite remarkable: you’re looking at the first vial of ‘starting material’ of the @AstraZeneca COVID-19 vaccine in Australia. @CSL will start making millions of doses from tomorrow – in anticipation of final approvals next year. @7NewsMelbourne pic.twitter.com/UkHzZNrAkF

— Blake Johnson (@BlakeJohnson) November 8, 2020

“The #Australian government… said on Thursday [it] will buy 40M #vaccine doses from @Novavax, and 10 million from @Pfizer and @BioNTech_Group… That adds to the 85M doses Australia has already committed to buy from @AstraZeneca and @CSL…” #COVID19 https://t.co/4pe1y0mEWl

— Mark Warner (@MAAWLAW) November 5, 2020

Morning Bell: #ASX200 to gain 0.2% at the open. VIC #COVID19 restrictions have been eased & @CSL is set to produce 30 mil #COVID19Vaccines. #Brexit talks to dominate this week, keep an eye on $LNK & $VUK. Trading ideas: $MQG & $BXB. #ausbiz #belldirect https://t.co/Qb1Xf7JJlo

— Bell Direct (@belldirect) November 8, 2020

Are you debating your holiday plans? Get some expert advice about how to stay safe, especially if you're living with a rare or chronic illness. https://t.co/5iXQVwsaUC

— CSL Behring (@CSLBehring) November 6, 2020

Help raise awareness this November – it's #Alpha1Awareness month – by learning more. It’s a rare hereditary respiratory condition sometimes called genetic #COPD. It’s estimated only 10% of patients are properly diagnosed…could you be one of them? https://t.co/tndZncDf1n

— CSL Behring (@CSLBehring) November 5, 2020

Scientists at #CSLBehring are offering some advice about how to clean up at home and prevent the spread of #COVID19. They tested several cleaning agents, including a commonly available household soap, and found they all killed the virus. https://t.co/LP7GuI673O

— CSL Behring (@CSLBehring) November 5, 2020

Today, the study design for our landmark Phase 3 AEGIS-II trial was published in @AmericanHeartJ Read more about our cardiovascular research program involving #heartattack survivors: https://t.co/WByn9r3ny6 @CMichaelGibson #cardiotwitter pic.twitter.com/go8GivEfAw

— CSL Behring (@CSLBehring) November 5, 2020

One key lesson from the #COVID19 pandemic is the need for global cooperation to develop potential therapeutics. #CSLBehring is proud to collaborate with our partners in the CoVIg-19 Plasma Alliance on a potential treatment. More here: https://t.co/La5JtJmMkp

— CSL Behring (@CSLBehring) November 2, 2020

#NEWS: Both the @US_FDA and @EMA_News have granted orphan drug designation to our investigational therapy for #SickleCellDisease Learn more: https://t.co/aJ36nNJ1JA @GregoryKatoMD pic.twitter.com/VghvWrIBpB

— CSL Behring (@CSLBehring) November 2, 2020

https://twitter.com/CSLBehring/status/1322931444545703938

CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patientshttps://t.co/dcDfXyJNgb @CSLBehring #cardiologist #doctor #cardio #cardiovascular #ECG #HeartNews #healthcare #medicaltechnology

— Cardiology 2.0 (@cardiology_2) November 5, 2020

.@CSLBehring's @johnkthompson60 shares advice on scaling #datascience — making the case for a #COE, building a team from scratch, setting priorities, and more: https://t.co/o5ivCh9qox pic.twitter.com/a49gANEJiA

— Domino Data Lab (@DominoDataLab) November 4, 2020

https://twitter.com/thalassaemiaTIF/status/1325715357408120835

Why is Liverpool the flu jab manufacturing capital of the country? Is this why the mayor is so keen to stay on Johnson's good side? Is there a vaccine contract up for grabs? There are at least three vaccine companies in Speke alone! #KBF #CovidVaccine https://t.co/2VRdszJEF9

— SarcasticSooooooz #JFT96 #KBF #Abetterway (@goldjerrygold1) November 4, 2020

Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020 https://t.co/dPjCGTf2BZ

— IMPharma News (@IMPharmaNews) November 2, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

The CoVIg-19 Plasma Alliance (Takeda, @bplplasmallc, @BiotestPlasma, @CSLBehring, @LFB_Group, @OctapharmaGroup, @AdmaBiologics, @BiomedPharmaGC, @sanquin, etc) has begun clinical production of a potential #COVID19 medicine. Help by donating plasma: https://t.co/q6Fe7VvHlG pic.twitter.com/Zcp4aNWpfh

— Takeda (@TakedaPharma) May 18, 2020

Takeda has joined forces with @bplplasmallc, @BiotestPlasma, @CSLBehring, @LFB_Group and @OctapharmaGroup to accelerate a potential treatment option for those at risk of serious complications from #COVID19. https://t.co/8MfTnO7olj pic.twitter.com/wimzKrVyh4

— Takeda (@TakedaPharma) April 23, 2020

Industry alliance brings together Takeda and other world-leading plasma companies, @BPLPlasmaLLC, @BiotestPlasma, @CSLBehring @LFB_Group and Octapharma, to accelerate development of a hyperimmune immunoglobulin medicine in the fight against #COVID19. https://t.co/ok9gZ1r1nf pic.twitter.com/mrpgUDg46l

— Takeda (@TakedaPharma) April 6, 2020

Ashfield proudly provides contact center support for #TheFightisInUs – joining global leaders, @Microsoft, @Takeda, @CSLBehring, @MayoClinic , @AdCouncil, @AmericasBlood in the campaign to collect life-saving #plasma from #COVID19 survivors. Learn more: https://t.co/J4vZzeYrpl pic.twitter.com/NKxwMWLxHl

— Ashfield Healthcare (@AshfieldCM) May 29, 2020

Australian biotech giant @CSL has formed a consortium with Takeda Pharmaceutical Company to develop a potential plasma therapy to fight #coronavirus. Story: https://t.co/TARpXMR76H pic.twitter.com/xNXtkLLd7v

— ManufacturersMonthly (@manmonthly) April 8, 2020

Toby Simon discussing the alliance between major producers of hyper-immune plasma therapies including @CSL_plasma @takeda and othershttps://t.co/fFH7rHJgUT #NewyorkBIO_COVID19

— NewYorkBIO (@newyorkbio) June 25, 2020

@CSLBehring is part of the CoVIg-19 Plasma Alliance that includes Biotest, BPL, LFB, Octapharma, Takeda, ADMA Biologics, BioPharma Plasma, GC Pharma, and Sanquin. @GatesFoundation is providing advisory support. Microsoft is providing technology. https://t.co/ctv0gLJiKI

— NCBIO (@ncbio) May 18, 2020

Biotest, BPL Group, LFB, and Octapharma have joined an alliance formed by CSL Behring and Takeda to develop a potential plasma-derived therapy for treating #COVID-19. https://t.co/yvjUnzLuVP @CSLBehring @TakedaPharma pic.twitter.com/YjtGyPdkQv

— Georgia Bio (@Georgia_Bio) April 6, 2020

CSL teams up with Takeda to create virus plasma treatmenthttps://t.co/S7Z6GXTj3T

— Financial Review (@FinancialReview) April 6, 2020

Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL https://t.co/dzdsNLhA5N

— cafepharma (@cafepharma) October 11, 2020

CSL and Takeda have isolated it and refined it into an anti-sera. CSL is the source for the plasma.
Trials begin this summer.https://t.co/nilSD0fo8G

— Timothy Gumm (@timothy_gumm) May 13, 2020

Japan approves #remdesivir to treat #COVID19; plus Takeda and CSL's Plasma Alliance will run its globulin trial with NIH, and a trio of Chinese biotechs partnered for an antibody therapy https://t.co/hKOoMUl3QM

— BioCentury (@BioCentury) May 8, 2020

As part of the global response against #COVID19 the #Swiss pharmaceutical company @OctapharmaGroup has joined with Biotest (Germany), BPL (UK), CSL Behring (Australia), Groupe LFB (France) and Takeda Pharma (Japan) to develop treatments. #SwissTechL39 https://t.co/UI3zppqkUt

— Swiss Embassy UK (@SwissEmbassyUK) April 16, 2020

‘It’s a humanitarian effort’: Led by Takeda and CSL Behring, a plasma coalition forms to fight #COVID-19. A new, worldwide coalition of plasma companies is seeking to develop and deliver a hyperimmune immunoglobulin therapy for… https://t.co/3HUIA8rTuX pic.twitter.com/LY0FsR10x4

— PIER MARIA FORNASARI (@PierFornasari) April 13, 2020

CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy @themotleyfool #stocks $TAK $CSLLY $EBS https://t.co/Lg69jmchXb

— Paula Schuck (@inkscrblr) April 10, 2020

CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy | NASDAQ https://t.co/uU7dcI4Nkl

— Economic Alliance of Kankakee County (@KankakeeCoEDC) April 9, 2020

quite a news here: big plasma-derived therapies' players (Biotest, Bio Products Laboratory, CSL, LFB, Octapharma and Takeda) join forces to immediately begin developing a non-company specific trademarked polyclonal hyperimmunoglobulin drug against SARS-CoV-2. https://t.co/agJaq44XX1

— Bertrand Delsuc (@BertrandBio) April 6, 2020

Says an organization w/ following roster of sponsors: 2019 Strategic Partners
Gold:
AstraZeneca
GSK
Merck & Co., Inc.
Pfizer Inc.
Sanofi Pasteur
Silver:
Janssen Therapeutics
Medicago Inc.
Bronze:
Seqirus, Inc. USA
Takeda https://t.co/DGLx3Lxfqh

— Plum Remson (@PlumRemson) November 10, 2019

Thank you again for our Virtual National Conference Sponsors for their continued support and dedication to the Alpha-1 Community. pic.twitter.com/A6ImAupRSS

— Alpha-1 Foundation (@AlphaFriend) June 29, 2020

Varicella Live Vaccine Market (impact of COVID-19) Demand, Growth and Opportunity 2020| Astellas Pharma Inc., CSL… https://t.co/02vQ6n1fqA >>> https://t.co/HTA6IsoHwv #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #healthcare #biotech

— Dr Timos Papagatsias (@_timos_) July 18, 2020

The Global Vaccines Market Growth & Major Players – Astellas , CSL, Johnson & Johnson https://t.co/CV4KYxOA1i #VaccinesMarket #GlobalVaccinesMarket #VaccinesMarketSize #VaccinesMarketShare #VaccinesMarketTrends #VaccinesMarketGrowth #VaccinesMarketFuture #Vaccines

— Kriti Singh (@KritiSi62917720) May 30, 2019

Key players in the market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), MedImmune, LLC… https://t.co/ZZYfSHHK27

— PressRelease.cc (@PressRelease_cc) October 28, 2019

CSL is proud 2 announce that Dr. Bill Carson, CEO of Otsuka Pharma. Development & Commercialization joined our advisory team @elginthompson

— Culture Shift Labs (@CultureShiftLab) March 27, 2014

United States Influenza Vaccines Market 2018-2025 Analysis by emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi TanabePharma and Biondvax Pharmaceuticals Ltd, Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca https://t.co/qQqrKL10Fm via @openPR

— DPI Research_Vaccine (@MarketR_Vaccine) November 5, 2018

Participants at the Asia Pacific and Japan Society of Hemostasis and Thrombosis conference shared perspectives on advances in #Haemophilia management, discussing options for individualised treatment #patientpromise pic.twitter.com/vJSgDfKyFh

— CSL (@CSL) July 9, 2018

To mark #WorldHaemophiliaDay, our colleagues in Japan share their heartfelt messages of support for the bleeding disorders community and demonstrate how we are driven everyday by our promise to patients. pic.twitter.com/CPGbZ7ULYj

— CSL (@CSL) April 17, 2018

Take a video tour of our new #CSLBehring office in Tokyo, #Japan. https://t.co/4mKVDWT1i6 pic.twitter.com/gPArofSVwx

— CSL Behring (@CSLBehring) July 15, 2019

We’re proud to bring 2 new options to #CIDP patients in Japan. https://t.co/HYxworDI6U pic.twitter.com/NCclP5p9ce

— CSL Behring (@CSLBehring) April 4, 2019

Our team in #Japan recently painted traditional Shisa sculptures as they reflected on past accomplishments and looked ahead to the future. pic.twitter.com/zOKXX5qCkG

— CSL Behring (@CSLBehring) August 9, 2017

Thank you to all – especially those in our Tokyo office – who helped bring our first #hemophilia product to Japan. https://t.co/MICGBFKdPg pic.twitter.com/gYYJpKe4fz

— CSL Behring (@CSLBehring) September 30, 2016

We're proud to bring our first #hemophilia product to Japan. https://t.co/sWn3BoCY3G pic.twitter.com/L6WvlTra6i

— CSL Behring (@CSLBehring) September 30, 2016

Our colleagues around the world took the #RedTieChallenge to support patients who have bleeding disorders. Japan! pic.twitter.com/Zdzm1PwMII

— CSL Behring (@CSLBehring) April 22, 2016

Despite the low awareness of patient groups in #Japan, healthcare professionals recognise the potential of patient representation in the #rarediseases space > https://t.co/bZIBH7dX3m via @CSLBehring pic.twitter.com/JcG4QtBbxy

— The Economist Intelligence Unit (@TheEIU) August 12, 2020

“Global biotherapeutics leader CSL Behring recently announced that Japan's Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with CIDP” https://t.co/jXmvuFEow5 pic.twitter.com/0J9uW53K2u

— CIDP Neuropathy (@CIDPNeuropathy) April 2, 2019

Japan Approves Berinert from @CSLBehring for Short-Term Prophylactic Treatment of HAE: https://t.co/6mZE48U2hd

— HAE International (HAEi) (@HAEDAY) March 24, 2017

CSL Behring's long-acting hemophilia B treatment Idelvion approved in Japan https://t.co/RsklhGEDr2 $QURE $ONCE $NVO $BAX

— Breaking News (@MarketCurrents) September 29, 2016

Takeda, Moderna partner up to bring 50M coronavirus shots to Japan | @TakedaPharma @Moderna_tx @Novavax @CSLBehring #Covid19 #Biotech #Vaccine #Deerfield #Cambridge #Massachusetts #Rockville #Maryland https://t.co/rP1SGKCnO9

— Pharm2Market (@pharm2market) October 31, 2020

U.S.A. アメリカ Vol.127（US Presidential Election 2020 米国大統領選挙）

All the below links are in English.

取り急ぎ以下貼っておきます。

US Presidential Election 2020 Vol.9　cspan、NewsHour、TIME、Newsweek、HuffPost、voxdotcom
US Presidential Election 2020 Vol.8　NPR、politico、thehill、drudgereportfeed、BreitbartNews、DailyCaller
US Presidential Election 2020 Vol.7　CBSNews、NBCNews、CNN、ABC、FoxNews、nytimes、washingtonpost

cf.
9/1　US Presidential Election 2020 Vol.6 (The Hill)
9/1　US Presidential Election 2020 Vol.5 (Politico)
9/1　US Presidential Election 2020 Vol.4 (Politico)
8/31　US Presidential Election 2020 Vol.3 (American Enterprise Institute, Heritage Foundation)
8/31　US Presidential Election 2020 Vol.2 (Brookings Institution)
8/29　US Presidential Election 2020 Vol.1 (conventions)
10/29　U.S.A. Vol.126（Joe Biden For President）
10/29　U.S.A. Vol.125（Donald J. Trump for President）

Germany ドイツ Vol.5（pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

Germany Vol.23 (pharmaceutical corporations: BioNTech)

上記リンク内に無い本日までのツイート

We provided an update on the potential timelines for the #COVID19 #vaccine candidate BNT162b2. We will seek approval only if the data provides a clear picture in three key areas: safety, efficacy, manufacturing quality. Read more in @WSJ by @bopanc. https://t.co/62njuhX3lu

— BioNTech SE (@BioNTech_Group) October 16, 2020

We are excited to welcome the latest addition to the BioNTech family: our colleagues in Marburg. The tech transfer is currently being made and we plan to start the production of potential #COVID19 vaccines in 2021. Welcome to #TeamBioNTech! pic.twitter.com/o9N26LmRoD

— BioNTech SE (@BioNTech_Group) November 2, 2020

One of the German #biotech firms working on a #CoronaVaccine, @BioNTech_Group, says results from study on effectiveness to come within next few days. Together with partner @pfizer will apply for FDA approval in 2 weeks. More on German vaccine development:https://t.co/cc92465OxM pic.twitter.com/YqwjNQds6O

— Germany Trade & Invest (@GTAI_com) October 30, 2020

https://twitter.com/InvestFlanders/status/1323176383582011394

Personalized #NeoantigenTherapy Plus #AntiPD1 | A Phase Ib Trial in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer | Lakshmi Srinivasan @BioNTech_Group @CellCellPress https://t.co/9NtpX0r8Bt | #2020_ReCapOct pic.twitter.com/2St8j5L624

— McHeyzer-Williams (@mmw_lmw) November 1, 2020

Engage with the community transforming the biotech sector at #BioIntegrates. Our one-day event will include interviews with Steve Bates, CEO, @BIA_UK and Sean Marett, Chief Business and Commercial Officer, @BioNTech_Group. Discover the full agenda: https://t.co/qynIgPU7rB pic.twitter.com/yJH4LzKuT2

— Life Science Integrates (@LSIntegrates) October 30, 2020

“The @UniofOxford/@AstraZeneca vaccine is expected to be one of the first from big #pharma to secure regulatory approval, along with @pfizer and @BioNTech_Group’s candidate" #ScienceNews #covid19news https://t.co/LgDPb8Eib4

— Life Science Rec. (@ScienceJobs) October 29, 2020

Comprehensive summary about the mRNA vaccine made in Mainz by Ugur, Özlem and the whole team of @BioNTech_Group and @tronmainz https://t.co/oqBicNHKrK

— Sebastian Boegel (@sebboeg) October 27, 2020

How a Little-known German Biotech Firm Founded by the Children of Turkish Immigrants Became a Leader in Global #Coronavirus Vaccine Race. ⁦My report via ⁦@WSJ⁩: https://t.co/FcSyXVccnC

— Bojan Pancevski (@bopanc) October 22, 2020

https://twitter.com/en_germany/status/1317834581048020993

@pfizer will apply for EUA from @US_FDA soon after they achieve the safety milestone of their experimental vaccine (developed with @BioNTech_Group) in the third week of November: https://t.co/WUtZ1UGrg5 #XerayaCapital #IndustryUpdates #COVID19 #Vaccine #Coronavirus pic.twitter.com/MQhAtL10oD

— Xeraya Capital (@xerayacapital) November 3, 2020

I continue to be #PfizerProud of all our colleagues, who delivered another strong quarter during these challenging times. The global phase 3 study for our #COVID19 vaccine candidate w/ @BioNTech_Group is ongoing at 150 sites with more than 42,000 participants enrolled. pic.twitter.com/ZCIzGMEDcJ

— AlbertBourla (@AlbertBourla) October 27, 2020

We are proud to organize the virtual @mrnaconference, the premier meeting destination for industry and academic professionals to explore the rapidly advancing science and business of #mRNA medicines. @BioNTech_Group @CureVacRNA @moderna_tx #eventplanning #vaccine #COVID19 pic.twitter.com/oKuuC0GpYA

— INTERPLAN Congress, Meeting & Event Management AG (@interplan_de) October 28, 2020

Richard B. Gaynor, MD, chair of the Accelerating Cancer Cures Advisory Committee, Damon Runyon board member, and President and Chief of Research and Development @BioNTech_Group U.S welcomes us to the virtual #CancerCures20 Symposium! pic.twitter.com/lArIzBNXKC

— Damon Runyon Cancer Research Foundation (@DamonRunyon) October 28, 2020

“@JNJNews plans to start testing its experimental #COVID19 #vaccine in youths aged 12 to 18 as soon as possible… Rival drugmaker @Pfizer has already begun testing the COVID-19 vaccine it is developing with Germany's @BioNTech_Group in children as young as 12.” #compliance https://t.co/PD9QxUCPag

— Mark Warner (@MAAWLAW) October 30, 2020

.@BioNTech_Group uses same mRNA technology as @moderna_tx. It never worked on anything, certainly not on vaccines, yet here we are.
Briefly discussed here: https://t.co/ccMuKcZYgi

— Leonid Schneider (visit my site for Covid19 cures) (@schneiderleonid) October 27, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

We announced an agreement with #Japan for 120m doses of our mRNA-based vaccine candidate. This is part of our commitment to address the global health crisis together with @Pfizer as we hope it may help in bringing the world together at the #TokyoOlympics. https://t.co/YUmpvqELru pic.twitter.com/VcubAIgTvd

— BioNTech SE (@BioNTech_Group) July 31, 2020

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan https://t.co/nR8eZ56zeB pic.twitter.com/yyabGBd1x2

— Reuters (@Reuters) October 20, 2020

Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan https://t.co/CPE5UL5WWR pic.twitter.com/iphKs1StYM

— Reuters (@Reuters) July 31, 2020

Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.https://t.co/jm6bN39Is7

— Hindustan Times (@htTweets) October 20, 2020

Pfizer, BioNTech start combined trials of #COVID19 vaccine candidate in Japanhttps://t.co/jm6bN2S73x pic.twitter.com/TiA3mzGXfn

— Hindustan Times (@htTweets) October 20, 2020

Japan to get 120 mn doses of #COVID19 vaccine from Pfizer, BioNTechhttps://t.co/dVvgeYAlhU pic.twitter.com/P8U5kvtWr7

— Hindustan Times (@htTweets) July 31, 2020

Russia says its secretive Covid-19 vaccine is “a Sputnik moment” – ready to be launched in less than 2 weeks.

As some countries develop their own, others are both making and buying vaccines, including Japan which is procuring 120M doses from Pfizer and BioNTech pic.twitter.com/pHRmIAQSGs

— TRT World (@trtworld) July 31, 2020

Today we announced an agreement with the Ministry of Health, Labor and Welfare in #Japan to supply 120M doses of our #COVID19 #vaccine candidate in collaboration with @BioNTech_Group, subject to regulatory approval: https://t.co/FBbQN3ciRF pic.twitter.com/U402NeO6WA

— Pfizer Inc. (@pfizer) July 31, 2020

We’re committed to helping governments have access to breakthroughs. Today we announced an agreement w/ Japan to supply, subject to regulatory approval, 120M doses of the mRNA-based COVID-19 vaccine candidate being co-developed by @Pfizer & @BioNTech_Group https://t.co/PmZEsrCRgZ

— AlbertBourla (@AlbertBourla) July 31, 2020

Pfizer and BioNTech agreed to provide Japan with 120 million doses of the Covid-19 vaccine they’re developing https://t.co/EGTGMDOuVl

— Bloomberg Technology (@technology) August 1, 2020

Pfizer, BioNTech to make 120M vaccine doses for Japan https://t.co/6JkbuzH5ug pic.twitter.com/ZYhPQd5dv9

— BNN Bloomberg (@BNNBloomberg) July 31, 2020

PFE Stock Down 0.5%, Pfizer and BioNTech to Supply Japan with 120M Doses of COVID-19 Vaccinehttps://t.co/UXUi8CUCgI pic.twitter.com/eYc2Wj14qd

— Coinspeaker (@coinspeaker) July 31, 2020

• Japan signs deal to secure 120 million dose of potential coronavirus vaccine, German pharmaceutical group BioNTech says https://t.co/XrAeG2tzpX

— ABS-CBN News (@ABSCBNNews) July 31, 2020

Pfizer $PFE, BioNTech $BNTX to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate https://t.co/Cww2CVC5jT pic.twitter.com/s2u8FoJU78

— Streetinsider.com (@Street_Insider) July 31, 2020

Pfizer, BioNTech score deal to supply 120M Covid-19 vaccine doses to Japan, writes @biotechvisigoth @medcitynews https://t.co/PSX9S2pMiz @BioNTech_Group $PFE $BNTX #COVID19

— MedCity News (@medcitynews) August 3, 2020

New post: Pfizer and BioNTech Supply Japan with 120 Million Doses of COVID-19 Vaccine Candidate BNT162 https://t.co/DLWtW6YYRt

— BiopharmaMASH (@bio_mash) August 1, 2020

Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate https://t.co/VajfZkzqfz @pfizer @BioNTech_Group More Transatlantic Life Science Business News at [LSUS] at https://t.co/HEEySVwfoy pic.twitter.com/PAdjZEeYAm

— [iito] Life Science (@iitoLifeScience) July 31, 2020

The #Covid19vaccine partnership of @BioNTech_Group and @pfizer inked its third supply pact in a week on Jul. 31. The #Japan government will take 120 million doses at an undisclosed price in the 2021 first half. It is the companies’ first #Asian agreement. https://t.co/jMHYIycNDk

— CHEManager International (@CHEManager_EU) August 4, 2020

US strikes $2.1bn #Covid19 vaccine deal with Sanofi $SAN and Glaxo $GSK, while Pfizer $PFE and BioNTech $BNTX to supply Japan with 120m vaccine candidate doses. More on the vaccine race in our podcast episode ➡️ https://t.co/LMsp4FXrx9 https://t.co/lOlbukINDP

— IGTV (@IGTV) July 31, 2020

Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said Friday. | @AFP https://t.co/d9cryfWhNC

— Inquirer (@inquirerdotnet) July 31, 2020

Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said. https://t.co/crihB500gj

— Philstar.com (@PhilstarNews) August 1, 2020

Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said Fridayhttps://t.co/v8o7oVWaA0 pic.twitter.com/M0IDFS0Egu

— AFP news agency (@AFP) July 31, 2020

Pfizer, BioNTech to supply 120 million doses of COVID-19 vaccine to Japan https://t.co/bqSgv5pZnW

— Business Today (@BT_India) July 31, 2020

#Japan signs deal with #BioNTech to secure 120 million doses of potential #coronavirus vaccine#TheNews

— The News (@thenews_intl) August 1, 2020

Pfizer, BioNTech to supply 120m doses of virus vaccine to Japan.https://t.co/G8kN9ZwzaV

— Nikkei Asia (@NikkeiAsia) July 31, 2020

Pfizer, BioNTech to supply 120 mil doses of experimental coronavirus vaccine to Japan: Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said… https://t.co/A5YL4MaTnk

— Japan Today News (@JapanToday) July 31, 2020

COVID-19 Vaccine Pipeline https://t.co/z9QJ2v4RBj via @kyodo_english #WHO @moderna_tx #NIAID @InovioPharma @BioNTech_Group #ClinicalResearch "Even if overseas vaccines have success and received special regulatory approval, the supply in Japan will be limited"

— ClinicalBid (@ClinicalBid) June 1, 2020

Japan signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech said Friday, July 31.

FULL STORY: https://t.co/eVEI6JXlcN pic.twitter.com/F8l7Ze6UUl

— Rappler (@rapplerdotcom) August 1, 2020

BioNTech says the first deliveries to Japan are planned for the first half of 2021. https://t.co/SjcHtrTMy2

— Rappler (@rapplerdotcom) August 1, 2020

Takeda estimates £162.50 million hit to operating loss as Novartis withdraws from European approval for Xiidra. #TakedaPharmaceutical #Novartis #EMA #BionTech #StockMarketNews #Coronavirus #Xiidra #OperatingLoss #Asia @EMA_News https://t.co/qgyUjrECut pic.twitter.com/8m4LRpX2I3

— iNVEZZ (@InvezzPortal) June 29, 2020

Boston Globe story yesterday on how small businesses in Central Square, #CambMA have been impacted by covid-19. https://t.co/ItouzHJizj. Biopharma companies in Central Sq incl Novartis, Takeda, Blueprint, Spero, Voyager, Beam, AbbVie, Fulcrum, Rheos, Neon/BioNtech, Intellia

— Pearl Freier (@PearlF) September 6, 2020

Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan | @Takedapharma @Novavax @Pfizer @BioNTech @AstraZeneca @UniofOxford #Vaccines #Covid19 #Biotech #MatrixM #Maryland #OperationWarpSpeed @JNJ https://t.co/82tpoKazFb

— Aspen Biosciences (@aspenbio) August 9, 2020

This week's EuroBiotech Report—Novo-Ablynx, Takeda-TiGenix, Scancell-BioNTech, Sanofi-Alnylam and Boehringer https://t.co/k5jkrKtv4M

— FierceBiotech (@FierceBiotech) January 11, 2018

U.K. イギリス Vol.31（pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

UK Vol.170 (pharmaceutical corporations: GlaxoSmithKline)

上記リンク内に無い本日までのツイート

Today we, together with @Sanofi and @Gavi, announced a Statement of Intent to make available 200m doses of our Sanofi/GSK co-developed #COVID19 #vaccine to the COVAX Facility, if successful in clinical trials. Learn more: https://t.co/OYGgP1QpVk pic.twitter.com/pnKYUy15Dq

— GSK (@GSK) October 28, 2020

Our intent to supply the COVAX Facility (led by @gavi and @WHO) with 200m doses of our co-developed #COVID19 #vaccine, if successful in clinical trials, is key to ensuring equitable access for every country in the world and protecting those most at risk. https://t.co/CcPiEsruRN pic.twitter.com/ufnuOfxVJ3

— GSK (@GSK) October 28, 2020

Our recent announcement that we will make available 200m doses of the #vaccine we’re co-developing with @Sanofi to COVAX, could, if successful in clinical trials, be a key milestone to helping end this #COVID19 #pandemic. https://t.co/aje70UKtQz

— GSK (@GSK) October 29, 2020

Interesting insights from global experts on #pandemic prevention and preparedness, including the role of #vaccines, as we learn from #COVID19. (Subscription may be required). https://t.co/AgxJLWB3rA

— GSK (@GSK) October 30, 2020

We are proud to join @ScienceMagazine Top 20 Employers. Testament to bringing together great science, new tech, and outstanding people. @ScienceCareers #Innovation #SCTopEmployer pic.twitter.com/VzLEyNRS9I

— GSK (@GSK) October 31, 2020

Thanks to our own @EstOdek for highlighting what needs to happen so #BIPOC are represented, visible & celebrated in #Science. We’re inspired by her to continue building an inclusive environment where all scientists feel valued & can bring their best and authentic selves to work! https://t.co/5QdufNCgm7

— GSK (@GSK) October 30, 2020

Collaboration in the wake of #COVID requires trust. Our CSO Hal Barron talks about how our partnership with @Vir_Biotech came together in 18 days and why focus on critical issues is key in the @WSJ article: https://t.co/M8aC4lyR4a pic.twitter.com/2YkaIyu0pP

— GSK (@GSK) October 24, 2020

Our CSO Hal Barron and President of Global Vaccines Roger Conner spoke with @joewalkerWSJ about how #COVID19 is ushering in a new era of industry collaboration. https://t.co/hkKwkyLzEb

— GSK (@GSK) October 24, 2020

#DYK Most adults in the US aren't vaccinated against #HepA? #Hepatitis A can be transmitted through close contact w/ an infected person or through contaminated food or water. Talk to your doctor about vaccination.
Visit ➡️ https://t.co/cEV0x0F39t #LiverAwarenessMonth #NOhep pic.twitter.com/MVI3DVzUZO

— GSK US (@GSKUS) October 27, 2020

We’re supporting the voice of the patient by working together to eliminate access barriers at the Alliance for Health Policy, Voice of the Patient Health Summit 2020. #AHPSummit20 #patientvoice https://t.co/vki0yDOUVo

— GSK US (@GSKUS) October 26, 2020

Sanofi and @GSK have signed a Statement of Intent with the @gavi @WHO @CEPIvaccines #COVAX facility to secure the distribution of our #COVID19 vaccine worldwide: https://t.co/NB1oald3wH #SanofiActs pic.twitter.com/BXD2sLoh0h

— Sanofi (@sanofi) October 28, 2020

This year has shown unprecedented collaboration across our industry. Congratulations, John Shiver, SVP of R&D, @sanofipasteur, in partnership with @GSK, on being named one of @FiercePharma’s most influential people in the fight against #COVID19. https://t.co/I458tte4iO

— Sanofi US (@SanofiUS) October 27, 2020

Today we are proud to announce our intent to supply 200 million doses of our adjuvanted recombinant protein #COVID19 vaccine, if approved to #COVAX alongside @GSK. This will help offer timely and cost-effective access to vaccines worldwide.@gavi Learn more https://t.co/uRDSulc3zb pic.twitter.com/JrWpcOrGqu

— Sanofi Pasteur (@sanofipasteur) October 28, 2020

We are extremely proud of John Shiver, Senior Vice President of Vaccines Global R&D, for being named by @FiercePharma as one of the most influential people in the fight against #COVID19, in partnership with @GSK. https://t.co/LAIf0GT1Pr

— Sanofi Pasteur (@sanofipasteur) October 27, 2020

We’re pleased to announce we have signed a Statement of Intent to procure 200 million doses of the @Sanofi and @GSK #COVID19 vaccine candidate for the #COVAX Facility! https://t.co/4Pv6BtXFtn @CEPIvaccines @WHO

— Gavi, the Vaccine Alliance (@gavi) October 28, 2020

Very pleased that @Gavi has signed a Statement of Intent with @Sanofi and @GSK to provide 200 million doses of their adjuvanted recombinant protein #COVID19 vaccine to the #COVAX Facility! https://t.co/pUO6ntVnLR

— Seth Berkley (@GaviSeth) October 28, 2020

Thank you @sanofi for your partnership and commitment alongside @GSK to ensure that safe and effective #COVID19 vaccines reach those in greatest need around the world. Pleased to welcome your commitment to the #COVAX goal of equitable vaccine access. #OneWorldProtected https://t.co/QraLhRsyVZ

— Seth Berkley (@GaviSeth) October 28, 2020

Thank you @GSK for working with @Sanofi to help ensure the most at-risk groups, such as healthcare workers, have rapid access to doses of #COVID19 vaccines. I welcome your commitment to global health security! #OneWorldProtected https://t.co/DmS1X7Vwea

— Seth Berkley (@GaviSeth) October 28, 2020

https://twitter.com/scibus/status/1321454739364728834
https://twitter.com/MSF_access/status/1321890170808008706
https://twitter.com/MSF_access/status/1321935282971807744

MSF calling for transparency from pharmaceutical corporations around price, supply and distribution of the potential future #COVID19 vaccine @GSK @sanofipasteur https://t.co/bvbHBaHvsT

— Shailly Gupta (@Shaillytweeting) October 29, 2020

Pharmaceutical giant @GSK will attend this year’s China International Import Expo. So what's the latest from #GSK on developing a #COVID19 #vaccine? And What are the highlights of their new products and services this year? pic.twitter.com/LjTM34TvhI

— Frontline (@Frontlinestory) October 29, 2020

EU approves Zejula as monotherapy in ovarian cancer @GSK https://t.co/hwtquaFAOL pic.twitter.com/JZbY6VsktN

— The Pharma Letter (@ThePharmaLetter) October 30, 2020

Sanofi & GSK to supply 200m doses of their Covid-19 vaccine to global distribution scheme

Read it here: https://t.co/fiz2Tjk0vK @sanofi l @GSK l @gavi pic.twitter.com/cpmV0nOaXB

— EPM Magazine (@EPM_Magazine) October 29, 2020

https://twitter.com/UN_SPHS/status/1321745134149656576

COVID-19 Vaccine Update: Sanofi, GSK to Supply COVAX with 200 Million Doses of Coronavirus Vaccinehttps://t.co/mPLw6qMCC5 #COVID19Vaccine @sanofi @GSK #COVAX

— LatestLY (@latestly) October 29, 2020

The CEO of SBC Member Organisation @GSK is optimistic that a COVID-19 vaccine could be widely available in 2021. Find out more here:https://t.co/HmZgQgjY3w #COVID19 #covidvaccine pic.twitter.com/nREQEZsV93

— StevenageBioscience (@SteBioCat) October 28, 2020

Partner of #DMTR pic.twitter.com/LZPuOiyZlS

— riddler (@riddler_smitb) October 28, 2020

News for #pharma #marketers: Thurs, Oct 29

– @Sanofi, @GSK give 200 million COVID-19 vaccine doses to Covax
– @Pfizer will not report coronavirus vaccine results this month
– Podcast: @Genentech’s Quita Highsmithhttps://t.co/W779ysMOAh

— MM+M Magazine (@MMMnews) October 29, 2020

Dave Tudor and John Arthur of the Medicines Manufacturing Innovation Centre mark the start of construction of the MMIC today – exciting times for UK Life Sciences, manufacturing and Scotland! @Ivan_McKee @ukCPI @UniStrathclyde @GSK @AstraZeneca @scotent https://t.co/7LUCJl1Qpv pic.twitter.com/7zRN1fCmy5

— Life Sciences Scot (@LifeSciScot) October 26, 2020

White House “Vaccine Czar” Dr. Slaoui is using loopholes and working under a shady contract to skirt ethics laws that would require him to sell all his stock in COVID vaccine manufacturers. @RepKatiePorter and I want @GSA_OIG to investigate his contract.https://t.co/6EMTPBd9RN

— Elizabeth Warren (@SenWarren) October 30, 2020

https://twitter.com/TomDoddFCDO1/status/1321891577317511169

Construction has started on the Medicines Manufacturing Innovation Centre – a collaboration between Strathclyde, @ukCPI & industry partners @AstraZeneca & @GSK. The new centre will put Scotland at the cutting edge of advanced pharmaceutical manufacturing.https://t.co/4DJIQBQk3q pic.twitter.com/mdcz8iWBAm

— University of Strathclyde (@UniStrathclyde) October 28, 2020

Thanks to UCL for a charming virtual graduation ceremony ⁦@ucleastman⁩ ⁦@ucl_slms⁩ Thanks to ⁦@GSK⁩ and ⁦@basem_uk⁩ ⁦@PaedDentEastman⁩ ⁦@IanNeedleman⁩ for supporting Dr Julie Gallagher on her journey pic.twitter.com/kHemprO2oC

— Oral Health in Sport (@oralhealthsport) October 29, 2020

Get to know some of the #SCTopEmployers in #biotech #pharma and find job opportunities—Explore the 2020 Top Employer Profiles for @GSK, @Roche, and @pfizer:https://t.co/EsP0urWYqx pic.twitter.com/mR7pv1ZvEZ

— Science Careers (@ScienceCareers) October 30, 2020

Congrats @GSKUS @GSK ! pic.twitter.com/4kZMvS5V0Q

— Talend (@Talend) October 29, 2020

Congratulations to @CondeNast, in partnership with @tweetPHM on behalf of @GSK, for winning the Online Video or Film category for their work on “Well, Actually”!#DPIWeek2020 #FierceAwards #BeFierce pic.twitter.com/l0dZPLZJmx

— Digital Pharma (@DigitalPharma) October 28, 2020

Impressive presentation of Prof. Koen Kas, @kaskoen, at the @GSK meets Belgian University Event, talking about several #digital examples to turn sick care into #Healthcare! https://t.co/tWpJXVPQgc

— FlandersVaccine (@FlandersVaccine) October 27, 2020

Thank you @Amgen, @chemocentryxinc, @genentech, @GSK and @sanguinebio for sponsoring our Newly Diagnosed Patient conference happening this Saturday! Come see for yourself how their support is already giving vasculitis patients a better quality of life. pic.twitter.com/LsUrh5Y9Ar

— Vasculitis Foundation (@VasculitisFound) October 29, 2020

500 followers up! Shout out to our amazing @AI4VBH industry partners – thank you for all support so far!@ainostics @Biotronics3D @CydarMedical @GEHealthcare @innersightlabs @KheironMedical @MiradaMedical @NetAppUK @nvidia @PerspectumGroup @SiemensHealth @GSK pic.twitter.com/RfPYGgQzVe

— London AI Centre for Value Based Healthcare (@AI4VBH) October 28, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

.@GSK and Daiichi Sankyo JV submits NDA for candidate #shingles vaccine in Japan https://t.co/rtg3TBFhCh pic.twitter.com/VJ1D4woI6R

— Pharma Tech Focus (@PharmaTechFocus) April 21, 2017

Anglo-Japanese JV announces Shingrix submission in Japan https://t.co/97zsKYDTBA #pharma @GSK @DaiichiSankyo @DaiichiSankyoJP

— The Pharma Letter (@ThePharmaLetter) April 19, 2017

Our president & CEO, Dr. Robert Preti says “since becoming part of Hitachi Chemical over a year ago, we have seen increasing interest in leveraging our PCT Global Service Platform both in the United States and Japan.” Learn about our partnership with @GSK: https://t.co/aS6Tfc9yKr

— Minaris Regenerative Medicine (@MinarisRM) October 30, 2018

#WIPOReSearch Member companies Eisai, GSK, Johnson & Johnson, and Takeda featured in November Partnership Hub Snapshot. Advancing drug discovery around #NTDs, #malaria, and #tuberculosis. https://t.co/rtLTaYv0uA @Eisai_SDGs, @GSK, @JNJGlobalHealth, @TakedaPharma, @WIPO pic.twitter.com/mnm0AJo3Ai

— BVGH (@BIOVentures) November 12, 2019

Great news that Takeda has joined the Open Targets drug discovery initiative. More here: https://t.co/XOHP4TPSpX @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/8SFnDO41B2

— Sanger Institute (@sangerinstitute) December 5, 2017

Takeda joins Open Targets drug discovery initiative. @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/XOHP4TPSpX pic.twitter.com/qPW97LuHPW

— Sanger Institute (@sangerinstitute) December 5, 2017

Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx

— Open Targets (@targetvalidate) June 21, 2019

GlaxoSmithKline, Teva, Takeda Investing in Global Sustainability Performance with the Responsible Health Initiative https://t.co/IfCIxQ9AQu via @ecovadis @GSK @Teva @tevapharmeurope @TakedaPharma @CDCGreenHealthy @bbchealth @Healthcare @HCPolicy @healthjourno1 @HCnewsEU

— EnvironmentalPartner (@MonikaWojcik) January 10, 2019

The Dementia Discovery Fund first launched in 2015 with $100 million in capital from a range of Big Pharma companies, the U.K. government and the non-profit Alzheimer's Research UK @Biogen @GSK @Johnson&Johnson @Lilly @Pfizer @Takeda @ARUK @DHSCgovuk https://t.co/tdtENajGGx

— The Dementia Discovery Fund (@TheDDFund) August 9, 2018

236 preclinical pharma-academia #partnerships in 2015. @GSK at the top, followed by Bristol-Myers Squibb and Takeda https://t.co/ThlU1DygfF

— Giuseppe Recchia (@GGRecchia) March 26, 2016

In new best practice, 8 #pharma companies found by #AMRB2020 to have clinical-stage medicines that qualify as truly new – meaning they are more likely to remain effective for longer against resistant pathogens.https://t.co/ElTPlzfSRr @GSK @nabriva @Otsuka @scynexis @Summitplc pic.twitter.com/WtaCMcJTuA

— Access to Medicine Foundation (@AtMIndex) February 15, 2020

Did you hear? #JNJ is joining forces with @GatesFoundation, @Evotec, @GSK and Otsuka to develop a universal #TB treatment regimen. Learn how this unique collaboration builds on the #JNJ commitment to transform #TB treatment and #endTB for good ➡️ https://t.co/lJP54H0eGv pic.twitter.com/3TTCK3UHdu

— Johnson & Johnson Global Health (@JNJGlobalHealth) March 5, 2020

#WIPOReSearch Member companies Eisai, GSK, Johnson & Johnson, and Takeda featured in November Partnership Hub Snapshot. Advancing drug discovery around #NTDs, #malaria, and #tuberculosis. https://t.co/rtLTaYv0uA @Eisai_SDGs, @GSK, @JNJGlobalHealth, @TakedaPharma, @WIPO pic.twitter.com/mnm0AJo3Ai

— BVGH (@BIOVentures) November 12, 2019

On #WorldMosquitoDay, we want to thank our pharmaceutical partners for donating over seven billion life-changing treatments for #elephantiasis since 2012. #beatntds #endtheneglect @Eisai_SDGs @GSK pic.twitter.com/sYOaNgSfDE

— UnitingtoCombatNTDs (@CombatNTDs) August 20, 2020

Together with the Haitian Ministry of Health (MSPP) and our partners @GSK and @Eisai_SDGs, we are closer to eliminating a painful & disfiguring disease. #BeatNTDs

Learn more about our work in Hispaniola here: https://t.co/qFvEVXsITc pic.twitter.com/orZuiKoDGV

— The Carter Center (@CarterCenter) March 23, 2020

New #paediatric treatments recently launched for #HIV #soiltransmittedhelminths #epilepsy and #pneumonia from 4 companies detailed in #atmi2018 today: @GSK @JNJNews @Merck @eisai …. #worldChildrensDay2018 #WorldChildrensDay https://t.co/qnb3DoC0m1

— Danny Edwards (@dannyjedwards) November 20, 2018

A huge thank you to our Corporate Volunteers that have been coming in to help us with maintenance and gardening around the site. Thank you to Eisai, @NatWest_Help Bishop's Stortford, '@GivingMachineUK , @GSK and @Tesco it is greatly appreciated! pic.twitter.com/fxNrSocTeO

— St Elizabeth's Centre (@St_Elizabeths) July 17, 2018

On #WorldNTDDay we celebrate our industry partnerships to #beatNTDs including the innovative Drug Discovery Booster to discover new drugs with @abbvie @AstellasUS @AstraZeneca @bmsnews @Eisai_SDGs @merckgroup Shionogi & @TakedaPharma. pic.twitter.com/j4Xgs60vO2

— Drugs for Neglected Diseases initiative (@DNDi) January 30, 2020

#NTD supply chain at #Merck attended by #Eisai, @pfizer @GSK #MSD @JNJNews @DeutschePostDHL on #schistosomiasis pic.twitter.com/ViNezXdIKC

— Merck (@merckgroup) June 28, 2016

#BreakingNews for #investors and #media: First approval of daprodustat (Duvroq) received in Japan.

— GSK (@GSK) June 29, 2020

https://twitter.com/GSK/status/1275710004411187206
https://twitter.com/GSK/status/880055699820093440

We’re partnering with @GatesFoundation, @wellcometrust & govts from Germany, Japan & Norway to #outsmartepidemics: https://t.co/vBcq9Mjy8q pic.twitter.com/wLo1DQidw6

— GSK (@GSK) January 19, 2017

.@GSK's drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas https://t.co/FMPlzKUJ69

— pharmaphorum (@pharmaphorum) June 29, 2020

Chasing #Astellas and #Mitsubishi, #GSK files for Japanese approval of oral #anemia drug https://t.co/X7cihSiIXO @FierceBiotech @GSK #daprodustat

— Plexus Ventures (@PlexusVentures) August 22, 2019

.@GSK lands 1st approval for #Duvroq as Japan greenlights drug for renal anemiahttps://t.co/ZK5FYlDf8Z $GSK pic.twitter.com/Fg8sAlJhGa

— Market Intelligence: Healthcare (@SPGMIHealthcare) June 29, 2020

GSK receives regulatory approval for Duvroq (daprodustat) in Japan in anaemia due to chronic kidney disease https://t.co/bsks1Wrmvg @GSK More Asian life science business news at [LSA] at https://t.co/BOlw85yA1L pic.twitter.com/s4Y83zBEcQ

— [iito] Life Science (@iitoLifeScience) June 29, 2020

GSK/ViiV: Dovato (dolutegravir/lamivudine), once-daily, single-pill, 2-drug regimen for HIV-1, granted marketing approval by Japan Ministry of Health, Labour and Welfare https://t.co/GF5h5nwtqV @GSK @ViiVHC More Asian life science business news at [LSA] at https://t.co/o0PHiM2bwA

— [iito] Life Science (@iitoLifeScience) January 15, 2020

Check out new #DRG epidemiology data and forecast on #herpeszoster incorporating the new #vaccine trends of #shingrix across the United States, Western Europe and Japan – live now! @DRGinsights @GSK #Shingles #VaccinesSaveLives https://t.co/r92nrjfqvg https://t.co/8zvj8CWrfZ

— DRG Epidemiology (@DRG_Epi) February 21, 2019

To take the shot or not? #DRG epidemiology report forecasts over 400 million people eligible for #influenzavaccine in 2019 across the United States, Western Europe and Japan. Check out the detailed report @DRGinsights @GSK #flu #vaccinateforlife #fluseason #Influenza https://t.co/TkI62MgvXF

— DRG Epidemiology (@DRG_Epi) January 30, 2019

Japan approval for Darzalex and Benlysta https://t.co/lCa7sYMMr4 @Genmab @JanssenGlobal @GSK #pharma

— The Pharma Letter (@ThePharmaLetter) September 27, 2017

.@GSK #SHINGRIX containing $AGEN QS-21 Stimulon® received approvals in US, Canada, and now in Europe & Japan for #prevention of #shingles in adults >=50 [https://t.co/qfmmLw3SRf]; Details here [https://t.co/Lw9n7kRgI1]. QS-21 is a part of Agenus’ neoantigen vaccine #AutoSynVax.

— Agenus Inc. ($AGEN) (@Agenus_Bio) March 26, 2018

#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC

Read: https://t.co/Ra1FDwHAXE @Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr

— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019

J&J, Sanofi and more look to ink national COVID-19 vaccine supply pacts in EU, Japan: reports | @AstraZeneca @JNJ @gatesfoundation @melindagates @BillGates @UniofOxford @BARDA @Sanofi @Moderna @Pfizer @BioNTech @Curevac @GSK #covid19 #vaccine #Biotech https://t.co/cRcjPrjCy9

— Aspen Biosciences (@aspenbio) July 19, 2020

On Monday, J. Sampson (@RobertWaltersJP), J. Spraggs (@GSK) and H. McLeish (@Japan_EY) kicked off the BCCJ's '#COVID19 Default to Action' webinar series.

Watch the full webinar, 'The Leadership Challenge', here: https://t.co/oix01kECMu pic.twitter.com/BhKaOagSdE

— British Chamber of Commerce in Japan (@BCCJapan) March 19, 2020

The nominees for the Diversity & Inclusion #2018BBAs are . . .
– @custommediakk
–@Freshfields Bruckhaus Deringer
– @GSK Japan
– @HoganLovells
-Intralink
– @LloydsofLondon Japan

Learn more about the nominees: https://t.co/KiQHd9dQX8 pic.twitter.com/ggzYLD8Qzk

— British Chamber of Commerce in Japan (@BCCJapan) October 30, 2018

Science and Technology 科学技術 Vol.12（pharmaceutical products 医薬品 Vol.5：influenza vaccines インフルエンザワクチン）

All the below links and excerpts are in English.

取り急ぎ標記関連リンクと当方作成の抜粋を以下のとおり貼っておきます。

Key Facts About Seasonal Flu Vaccine | @CDCgov

Flu Vaccination
How do flu vaccines work?
Flu vaccines cause antibodies to develop in the body about two weeks after vaccination. These antibodies provide protection against infection with the viruses that are used to make the vaccine.
The seasonal flu vaccine protects against the influenza viruses that research indicates will be most common during the upcoming season. Most flu vaccines in the United States protect against four different flu viruses (“quadrivalent”); an influenza A (H1N1) virus, an influenza A (H3N2) virus, and two influenza B viruses. There are also some flu vaccines that protect against three different flu viruses (“trivalent”); an influenza A (H1N1) virus, an influenza A (H3N2) virus, and one influenza B virus. Two of the trivalent vaccines are designed specifically for people 65 and older to create a stronger immune response.
What kinds of flu vaccines are available?
CDC recommends use of any licensed, age-appropriate influenza vaccine during the 2020-2021 influenza season, including inactivated influenza vaccine [IIV], recombinant influenza vaccine [RIV], or live attenuated influenza vaccine (LAIV). No preference is expressed for any influenza vaccine over another. Both trivalent (three-ingredient) and quadrivalent (four-ingredient) influenza vaccines will be available.
Quadrivalent flu vaccines include:
Standard-dose quadrivalent influenza shots that are manufactured using virus grown in eggs. These include Afluria Quadrivalent, Fluarix Quadrivalent, FluLaval Quadrivalent, and Fluzone Quadrivalent. Different influenza shots are licensed for different age groups. These four vaccines are approved for people 6 months of age and older. Most influenza shots are given in an arm muscle with a needle. One quadrivalent influenza shot (Afluria Quadrivalent) can be given either with a needle (for people aged 6 months and older) or with a jet injector (for people aged 18 through 64 years only). …
Are any of the available flu vaccines recommended over others?
…the Advisory Committee on Immunization Practices (ACIP) recommends…including inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV), or live attenuated nasal spray influenza vaccine (LAIV4)…
Who Should Not Be Vaccinated?
… Factors that can determine a person’s suitability for vaccination, or vaccination with a particular vaccine, include a person’s age, health (current and past) and any allergies to flu vaccine or its components. …
Flu and COVID-19
Does a flu vaccine increase your risk of getting COVID-19?
Vaccine Effectiveness
Can I get seasonal flu even though I got a flu vaccine this year?
What protection does a flu vaccine provide if I do get sick with flu?
Vaccine Benefits
What are the benefits of flu vaccination?
Vaccine Match
What if circulating viruses and the vaccine viruses are different?
Why is there sometimes not a good match between a vaccine virus and circulating viruses?
Flu viruses are constantly changing (called “antigenic drift”) ? they can change from one season to the next or they can even change within the course of one flu season. Experts must pick which viruses to include in the vaccine many months in advance in order for vaccine to be produced and delivered on time. …
… While all influenza viruses undergo changes when they are grown in eggs, changes in influenza A(H3N2) viruses are more likely to result in antigenic changes compared with changes in other influenza viruses. These so-called “egg-adapted changes” are present in most of the vaccine viruses recommended for use in egg-based vaccine production and may reduce their potential effectiveness against circulating influenza viruses. …
Vaccine Side Effects (What to Expect)
Can a flu vaccine give me flu?
No, a flu vaccine cannot cause flu illness. …
What side effects can occur after getting a flu vaccine?

Flu Vaccine (Flu Shot) | @MedicineNet
Facts you should know about the influenza vaccine (flu shot)
・Types of influenza (flu) vaccines include the injection (killed virus), recombinant (made without flu virus), and nasal spray vaccines (containing live virus). …
What is influenza (flu)?
… Flu is a respiratory infection, that is, an infection that develops primarily in the lungs. People often call respiratory infections caused by other viruses the flu, but this is incorrect. These other infections are usually categorized as URIs (upper respiratory infections) and have multiple causes. …
Influenza viruses are divided scientifically into three types, designated A, B, and C. Influenza types A and B are responsible for epidemics of respiratory illness that occur almost every winter. Influenza type C usually causes either a very mild respiratory illness or no symptoms at all; it does not cause epidemics and does not have the severe public health impact of influenza types A and B. Type A viruses are divided into subtypes and are named based on differences in two viral surface proteins called hemagglutinin (H) and neuraminidase (N). There are 16 known H subtypes and nine known N subtypes. …
The so-called swine flu pandemic of 2009 was caused by a novel influenza A virus designated H1N1 based upon its surface protein types. This virus was originally referred to as swine flu because many of the genes in this new virus were very similar to influenza viruses that normally occur in pigs in North America. However, this virus was actually quite different from the typical swine flu viruses found in pigs.

Types of seasonal influenza vaccine | @WHO_Europe
Two types of influenza vaccine are widely available: inactivated influenza vaccines (IIV) and live attenuated influenza vaccines (LAIV). Traditionally, influenza vaccines (both IIV and LAIV) have been produced to protect against 3 different seasonal influenza viruses (also called trivalent vaccines). In most countries this is still the case and the current trivalent vaccines contain influenza A(H3N2), pandemic A(H1N1) and 1 of 2 influenza B lineage viruses. However, recently vaccines which protect against 4 different viruses, including both influenza B lineage viruses (quadrivalent vaccines), have become available in some countries. …
Annual selection of viruses
The composition of influenza vaccines (both IIV and LAIV) are updated annually by WHO based on information gathered from the Global Influenza Surveillance and Response System (GISRS)…

Flu vaccine | @NHSuk
Flu vaccine and coronavirus (COVID-19)
Flu vaccination is important because:
・if you’re at higher risk from coronavirus, you’re also more at risk of problems from flu
・if you get flu and coronavirus at the same time, research shows you’re more likely to be seriously ill
・it’ll help to reduce pressure on the NHS and social care staff who may be dealing with coronavirus
If you’ve had COVID-19, it’s safe to have the flu vaccine. It’ll be effective at helping to prevent flu.

Influenza Vaccine for the 2020-2021 Season | @US_FDA
Influenza Vaccine (Flu Shot and Nasal Spray) for Adults | @WebMD
Q&A on Influenza (English; 11/21/2019) | 厚生労働省

Science and Technology 科学技術 Vol.11 ／ #Coronavirus #コロナウイルス Vol.13（pharmaceutical products 医薬品 Vol.4：drugs 治療薬）

All the below links and excerpts are in English.

リンクと当方作成の抜粋を取り急ぎ以下のとおり貼っておきます。

COVID-19 (coronavirus) drugs: Are there any that work? | @MayoClinic
… Remdesivir …
・Antiviral drugs. In addition to remdesivir, other antiviral drugs being tested include favipiravir and merimepodib. …
・Dexamethasone. …reduces the risk for deaths by about 30% for people on ventilators and by about 20% for people who needed supplemental oxygen. … Other corticosteroids, such as prednisone, methylprednisolone or hydrocortisone, may be used if dexamethasone isn’t available. However, their effectiveness isn’t yet known. …
・Anti-inflammatory therapy. …
・Immune-based therapy. … Convalescent plasma is blood donated by people who’ve recovered from COVID-19. …mesenchymal stem cells and monoclonal antibodies.
・… Researchers study amlodipine and losartan. But it’s not yet…
・Hydroxychloroquine and chloroquine. These malaria drugs… the FDA withdrew that authorization…
・Drugs to prevent COVID-19. …

The Latest Research on COVID-19 Treatments and Medications in the Pipeline (10/23/2020) | @GoodRx
Commonly used treatments for COVID-19 and therapies with emergency use authorizations (EUAs)
・Remdesivir (Veklury)
・Dexamethasone
・Convalescent plasma
New treatments in early phase studies
・Monoclonal antibodies (MABs) … Regeneron and Eli Lilly are two companies that both have MABs in development for COVID-19, currently called REGN-COV2 and LY-CoV555, respectively. …
Treatments that the NIH recommend against using for COVID-19
・Hydroxychloroquine and chloroquine
・Azithromycin … One research group looked at azithromycin in combination with hydroxychloroquine for COVID-19. They reported that 93% of patients cleared the virus after 8 days, but there was no control group so we don’t know if people would have cleared the virus on their own without the medications. There are concerns about potentially serious side effects when using azithromycin and hydroxychloroquine together. The NIH currently recommends against using azithromycin for COVID-19.
・Tocilizumab (Actemra) and other IL-6 inhibitors … By blocking IL-6, tocilizumab helps to calm down the immune system and is believed to also help with managing cytokine storms.
Research on tocilizumab started with a study from France, which reported that people who got tocilizumab were less likely to require ventilation or die. Another study from Italy found that those who got tocilizumab had a lower death rate, though about the same percentage of patients from both groups needed ventilators. On the other hand, tocilizumab did not help COVID-19 patients with early-stage pneumonia. A phase 3 study from the manufacturer also found that tocilizumab did not help for hospitalized COVID-19 patients with severe pneumonia. …
… They showed that patients with severe symptoms who got Kevzara did worse compared to placebo, but patients who had even more severe (critical) symptoms improved compared to placebo. …
・Kinase inhibitors … acalabrutinib (Calquence); baricitinib (Olumiant); ruxolitinib (Jakafi); tofacitinib (Xeljanz) …
・Interferons
・Kaletra (lopinavir/ritonavir)
・Ivermectin
Repurposed medications with minimal COVID-19 data
・Tamiflu (oseltamivir)
・Avigan (favipiravir) and other antiviral medications … In vitro studies have shown that high doses of favipiravir were able to prevent human cells from being infected with SARS-CoV-2. …
・Colcrys (colchicine)

Coronavirus Drug and Treatment Tracker (10/29/2020) | @nytimes

Blocking the Virus – Antivirals can stop viruses such as H.I.V. and hepatitis C from hijacking our cells. …
・Remdesivir
・Favipiravir
・Molnupiravir
・Recombinant ACE-2
・Ivermectin
・Oleandrin
・Lopinavir and ritonavir
・Hydroxychloroquine and chloroquine
Mimicking the Immune System -… Drugs might help people who can’t mount an adequate defense.
・Convalescent plasma
・Monoclonal antibodies
・Interferons
Putting Out Friendly Fire – The most severe symptoms of Covid-19 are the result of the immune system’s overreaction to the virus. …
・Dexamethasone and Other Corticosteroids
・Cytokine Inhibitors
・Blood filtration systems
・Stem cells
Other Treatments …
Pseudoscience and Fraud …

Treatments for COVID-19: What helps, what doesn’t, and what’s in the pipeline (10/23/2020) | @HarvardHealth

U.S.A. Vol.126（Joe Biden For President）

The below excerpts are on our own.

BUILD BACK BETTER: JOE BIDEN’S JOBS AND ECONOMIC RECOVERY PLAN FOR WORKING FAMILIES
… In this time of crisis, Joe Biden has a plan to create millions of good-paying jobs and to give America’s working families the tools, choices, and freedom they need to build back better.
That starts with a real strategy to deal with the pandemic. We can’t solve the jobs crisis until we solve the public health crisis. …
Biden will also provide further immediate relief to working families, small businesses, and communities. Biden will:
– Provide state, local, and tribal governments with the aid they need so educators, firefighters and other essential workers aren’t being laid off.
– Extend COVID crisis unemployment insurance to help those who are out of work.
– Provide a comeback package for Main Street businesses and entrepreneurs.
And, Biden will immediately put people to work by enlisting them to help fight the pandemic, including through a Public Health Jobs Corps.
… The Biden plan will mobilize the American people in service of four bold, national efforts to address four great national challenges. As President, Biden will:
– Mobilize American manufacturing and innovation to ensure that the future is made in America, and in all of America. …
– Mobilize American ingenuity to build a modern infrastructure and an equitable, clean energy future. …
– Mobilize American talent and heart to build a 21st century caregiving and education workforce which will help ease the burden of care for working parents, especially women. …
– Mobilize across the board to advance racial equity in America. …
Building back better means an updated social contract that treats American workers and working families as essential at all times, not just times of crisis…a decent wage, at least $15 per hour…universal paid sick days and 12 weeks of paid family and medical leave…
Building back better means helping small businesses and entrepreneurs come out the other side of this crisis strong, while demanding more from corporate America. …
…reversing some of Trump’s tax cuts for corporations and imposing common-sense tax reforms that finally make sure the wealthiest Americans pay their fair share.

A TALE OF TWO TAX POLICIES: TRUMP REWARDS WEALTH, BIDEN REWARDS WORK
I. Trump’s Tax Proposal In An Economic Crisis: A New Billionaire Tax Cut
… In Trump’s America, a working family making $65,000 will pay 22% on every extra dollar they earn, not including payroll taxes, while billionaires will pay just 15% on their profits from investments. …
II. Trump’s Tax Record: Billions For Foreign Investors And Large Multinational Corporations
… In 2018, in the wake of the Trump tax giveaway, 91 companies in the Fortune 500 paid no federal taxes on their income and another 56 paid less than 5 percent. …
Just a few examples of the harmful impact of Trump’s corporate tax giveaway include:
– Wells Fargo saved nearly $6.5 billion from the tax giveaway in 2018 and 2019, then authorized $40 billion worth of stock buybacks, raised interest rates on borrowers, and announced that it would lay off up to 26,000 workers.
– The pharmaceutical giant AbbVie received a $1.3 billion tax handout, announced $10 billion worth of buybacks, then increased prices for more than 10 of its products, including the arthritis medication, Humira.
– JPMorgan Chase pocketed $8.76 billion in tax breaks in 2018 and 2019 and yet last year still charged consumers $2 billion in overdraft fees, and cut hundreds of jobs.
– Harley-Davidson announced it would repurchase almost $700 million worth of its own stock, slash 350 manufacturing jobs, and shift some of its production overseas.
– AT&T cut thousands of jobs, while Trump gave them $1 billion in federal contracts and a $3 billion per year tax cut.
– Boeing offshored more than 2,000 U.S. jobs and announced billions in stock buybacks while receiving $29 billion in contracts and a $1.1 billion tax cut from Trump.
III. Biden’s Plan: Make The Wealthy And Corporations Pay Their Fair Share, And Provide Tax Relief For Working Families
… Joe Biden will not raise taxes on anyone making less than $400,000. Period. But he will ask wealthy Americans and big corporations to pay their fair share, including by:
– Raising the corporate tax rate to 28 percent.
– Requiring a true minimum tax on ALL foreign earnings of United States companies located overseas so that we do our part to put an end to the global race to the bottom that rewards global tax havens. This will be 21% — TWICE the rate of the Trump offshoring tax rate and will apply to all income.
– Imposing a tax penalty on corporations that ship jobs overseas in order to sell products back to America.
– Imposing a 15% minimum tax on book income so that no corporation gets away with paying no taxes.
– Raising the top individual income rate back to 39.6 percent.
– Asking those making more than $1 million to pay the same rate on investment income that they do on their wages.
…

THE BIDEN PLAN TO BUILD A MODERN, SUSTAINABLE INFRASTRUCTURE AND AN EQUITABLE CLEAN ENERGY FUTURE
… Amidst the COVID-19 pandemic, he ignored public health experts, praised the Chinese government, and failed to take the actions needed to protect the American people. …
Just as with COVID-19, Donald Trump has denied science and failed to step up in the face of the climate crisis. He has called it a hoax. He has allowed our infrastructure to deteriorate and farmers’ fields to flood. He has held back American workers from leading the world on clean energy, giving China and other countries a free pass to outcompete us in key technologies and the jobs that come with them. …
… He will launch a national effort aimed at creating the jobs we need to build a modern, sustainable infrastructure now and deliver an equitable clean energy future.
… Biden will make a $2 trillion accelerated investment…
– Infrastructure:…from roads and bridges to green spaces and water systems to electricity grids and universal broadband…
– Auto Industry: Create 1 million new jobs…
– Transit: Provide every American city with 100,000 or more residents with high-quality, zero-emissions public transportation options through flexible federal investments with strong labor protections…
– Power Sector:…a carbon pollution-free power sector by 2035. …
– Buildings: Upgrade 4 million buildings and weatherize 2 million homes over 4 years, creating at least 1 million good-paying jobs with a choice to join a union…
– Housing: Spur the construction of 1.5 million sustainable homes and housing units.
– Innovation: Drive dramatic cost reductions in critical clean energy technologies, including battery storage, negative emissions technologies, the next generation of building materials, renewable hydrogen, and advanced nuclear…
– Agriculture and Conservation: Create jobs in climate-smart agriculture, resilience, and conservation, including 250,000 jobs plugging abandoned oil and natural gas wells and reclaiming abandoned coal, hardrock, and uranium mines…
– Environmental Justice…
Biden also reaffirms his commitment to fulfill our obligation to the workers and communities who powered our industrial revolution and decades of economic growth, as outlined in his original climate plan. …
– BUILD A MODERN INFRASTRUCTURE …
– POSITION THE AMERICAN AUTO INDUSTRY TO WIN THE 21ST CENTURY …
– CREATE MILLIONS OF JOBS PRODUCING CLEAN ELECTRIC POWER FOR AMERICAN FAMILIES AND BUSINESSES …
– UPGRADE THE BUILDING SECTOR: RETROFITTING BUILDINGS, UPGRADING SCHOOLS, AND BUILDING HOMES ACROSS AMERICA …
– PURSUE A HISTORIC INVESTMENT IN CLEAN ENERGY INNOVATION … A major focus of Biden’s commitment to increase federal procurement by $400 billion in his first term…
– INVEST IN SUSTAINABLE AGRICULTURE AND CONSERVATION …
– SECURE ENVIRONMENTAL JUSTICE AND CREATE EQUITABLE ECONOMIC OPPORTUNITY …

LIFT EVERY VOICE: THE BIDEN PLAN FOR BLACK AMERICA
THE BIDEN AGENDA FOR THE LATINO COMMUNITY

BIDEN-SANDERS UNITY TASK FORCE RECOMMENDATIONS (PDF)